Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 321091, 8 pages
http://dx.doi.org/10.1155/2015/321091
Review Article

Pharmacogenomics and Herb-Drug Interactions: Merge of Future and Tradition

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
2Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China

Received 1 December 2014; Revised 20 January 2015; Accepted 21 January 2015

Academic Editor: Roja Rahimi

Copyright © 2015 Mou-Ze Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Center for Complementary and Alternative Medicine, http://nccam.nih.gov/about.
  2. D. M. Eisenberg, R. C. Kessler, C. Foster, F. E. Norlock, D. R. Calkins, and T. L. Delbanco, “Unconventional medicine in the United States: prevalence, costs, and patterns of use,” The New England Journal of Medicine, vol. 328, no. 4, pp. 246–252, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hori, I. Mihaylov, J. C. Vasconcelos, and M. McCoubrie, “Patterns of complementary and alternative medicine use amongst outpatients in Tokyo, Japan,” BMC Complementary and Alternative Medicine, vol. 8, article 14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Teng, K. Jin, K. He et al., “Use of complementary and alternative medicine by cancer patients at zhejiang university teaching hospital zhuji hospital, China,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 7, no. 4, pp. 322–330, 2010. View at Google Scholar · View at Scopus
  5. H.-J. Seo, S.-M. Baek, S. G. Kim, T.-H. Kim, and S. M. Choi, “Prevalence of complementary and alternative medicine use in a community-based population in South Korea: a systematic review,” Complementary Therapies in Medicine, vol. 21, no. 3, pp. 260–271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Nakao, Y. Muramoto, M. Hisadome et al., “The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6,” European Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 345–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D. E. Johnson, “Interactions between traditional Chinese medicines and Western therapeutics,” Current Opinion in Drug Discovery & Development, vol. 13, no. 1, pp. 50–65, 2010. View at Google Scholar · View at Scopus
  8. S. M. Asdaq and M. N. Inamdar, “Potential of garlic and its active constituent, S-allyl cysteine, as antihypertensive and cardioprotective in presence of captopril,” Phytomedicine, vol. 17, no. 13, pp. 1016–1026, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gharagozloo, B. Moayedi, M. Zakerinia et al., “Combined therapy of silymarin and desferrioxamine in patients with β-thalassemia major: a randomized double-blind clinical trial,” Fundamental & Clinical Pharmacology, vol. 23, no. 3, pp. 359–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Tomlinson, M. Hu, and V. W. Y. Lee, “In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?” Molecular Nutrition and Food Research, vol. 52, no. 7, pp. 799–809, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-W. Chen, K. B. Sneed, S.-Y. Pan et al., “Herb-drug interactions and mechanistic and clinical considerations,” Current Drug Metabolism, vol. 13, no. 5, pp. 640–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Zhang, B. Ge, L. Zhou, T.-N. Lam, and Z. Zuo, “Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin,” Journal of Ethnopharmacology, vol. 154, no. 3, pp. 672–686, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. P. van Strater and J. P. A. M. Bogers, “Interaction of St John's wort (Hypericum perforatum) with clozapine,” International Clinical Psychopharmacology, vol. 27, no. 2, pp. 121–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Naccarato, D. Yoong, and K. Gough, “A potential drug-herbal interaction between Ginkgo biloba and efavirenz,” Journal of the International Association of Physicians in AIDS Care, vol. 11, no. 2, pp. 98–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Tian, Z.-Y. Cheng, H. Jin, J. Gao, and H.-L. Qiao, “Inhibitory effects of baicalin on the expression and activity of CYP3A induce the pharmacokinetic changes of midazolam in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 179643, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Shao and L. Jia, “Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke,” Trends in Pharmacological Sciences, vol. 34, no. 2, pp. 85–86, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Li, J. Hu, B. Wang et al., “Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp,” Toxicology and Applied Pharmacology, vol. 275, no. 2, pp. 163–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Li, H. Hu, S. Xu, Q. Zhou, and S. Zeng, “Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions,” Current Drug Metabolism, vol. 13, no. 5, pp. 615–623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Brantley, A. A. Argikar, Y. S. Lin, S. Nagar, and M. F. Paine, “Herb-drug interactions: challenges and opportunities for improved predictions,” Drug Metabolism and Disposition, vol. 42, no. 3, pp. 301–317, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Shi and U. Klotz, “Drug interactions with herbal medicines,” Clinical Pharmacokinetics, vol. 51, no. 2, pp. 77–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-Y. Han, H.-Y. Zhao, N. Zhou, F. Zhou, and P.-P. Li, “Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes,” Journal of Ethnopharmacology, vol. 151, no. 1, pp. 210–217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Song, M. Hong, M. Y. Lee et al., “Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6,” Food and Chemical Toxicology, vol. 59, pp. 549–553, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Fan, J.-C. Wang, F. Jiang et al., “Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation,” European Journal of Clinical Pharmacology, vol. 65, no. 4, pp. 403–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Gorski, S.-M. Huang, A. Pinto et al., “The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo,” Clinical Pharmacology and Therapeutics, vol. 75, no. 1, pp. 89–100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Q. P. Yin, B. Tomlinson, M. M. Y. Waye, A. H. L. Chow, and M. S. S. Chow, “Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole,” Pharmacogenetics, vol. 14, no. 12, pp. 841–850, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Uno, N. Yasui-Furukori, T. Takahata, K. Sugawara, and T. Tateishi, “Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes,” The Journal of Clinical Pharmacology, vol. 45, no. 6, pp. 690–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Miura, H. Kagaya, H. Tada et al., “Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole,” Xenobiotica, vol. 36, no. 1, pp. 95–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Chen, D.-S. Ouyang, Z. Kang et al., “Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers,” Xenobiotica, vol. 42, no. 6, pp. 596–602, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Han, D. Guo, Y. Chen, Y. Chen, Z.-R. Tan, and H.-H. Zhou, “Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers,” European Journal of Clinical Pharmacology, vol. 65, no. 6, pp. 585–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. X.-D. Wang, J.-L. Li, Q.-B. Su et al., “Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme,” British Journal of Clinical Pharmacology, vol. 67, no. 2, pp. 255–261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Xu, K. M. Williams, W. S. Liauw, M. Murray, R. O. Day, and A. J. McLachlan, “Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide,” British Journal of Pharmacology, vol. 153, no. 7, pp. 1579–1586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Rengelshausen, M. Banfield, K.-D. Riedel et al., “Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics,” Clinical Pharmacology and Therapeutics, vol. 78, no. 1, pp. 25–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. L.-S. Wang, G. Zhou, B. Zhu et al., “St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole,” Clinical Pharmacology and Therapeutics, vol. 75, no. 3, pp. 191–197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-S. Wang, B. Zhu, A. M. A. El-Aty et al., “The influence of St. John's wort on CYP2C19 activity with respect to genotype,” Journal of Clinical Pharmacology, vol. 44, no. 6, pp. 577–581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Li, F.-M. Lian, D. Guo et al., “The rs1142345 in TPMT affects the therapeutic effect of traditional hypoglycemic herbs in prediabetes,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 327629, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Fan, G. Wang, L.-S. Wang et al., “Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole,” Acta Pharmacologica Sinica, vol. 28, no. 10, pp. 1685–1692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Imanaga, T. Kotegawa, H. Imai et al., “The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans,” Pharmacogenetics and Genomics, vol. 21, no. 2, pp. 84–93, 2011. View at Google Scholar
  38. L. Fan, W. Zhang, D. Guo et al., “The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1,” Clinical Pharmacology and Therapeutics, vol. 83, no. 3, pp. 471–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Hu, E. A. Ehli, J. J. Hudziak, and G. E. Davies, “Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region,” Pharmacogenomics Journal, vol. 12, no. 5, pp. 372–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. E. B. Mougey, J. E. Lang, X. Wen, and J. J. Lima, “Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast,” Journal of Clinical Pharmacology, vol. 51, no. 5, pp. 751–760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J.-H. Kim, S. R. Kim, I.-S. Song et al., “Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts,” Phytotherapy Research, vol. 25, no. 8, pp. 1141–1147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Q. Zhou, Z. Ye, Z. Ruan, and S. Zeng, “Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe,” Journal of Ethnopharmacology, vol. 146, no. 3, pp. 744–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Gervasini, S. Vizcaino, J. A. Carrillo, M. J. Caballero, and J. Benitez, “The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1C3435T polymorphisms and gender on the urinary excretion of the metabolites of the H1-receptor antihistamine ebastine: a pilot study,” British Journal of Clinical Pharmacology, vol. 62, no. 2, pp. 177–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Hu, V. W. L. Mak, O. Q. P. Yin, T. T. W. Chu, and B. Tomlinson, “Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 2, pp. 104–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. U. I. Schwarz, H. Hanso, R. Oertel et al., “Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol,” Clinical Pharmacology and Therapeutics, vol. 81, no. 5, pp. 669–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Fan, G. Zhou, D. Guo et al., “The pregnane X receptor agonist st johns wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide,” Clinical Pharmacokinetics, vol. 50, no. 9, pp. 605–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Wang, H. L. McLeod, and R. M. Weinshilboum, “Genomics and drug response,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1144–1153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Hu, D. Q. Wang, Y. J. Xiao, V. W. L. Mak, and B. Tomlinson, “Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters,” Current Pharmaceutical Biotechnology, vol. 13, no. 9, pp. 1718–1730, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Hu, L. Fan, H.-H. Zhou, and B. Tomlinson, “Theranostics meets traditional Chinese medicine: rational prediction of drug-herb interactions,” Expert Review of Molecular Diagnostics, vol. 12, no. 8, pp. 815–830, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. I. Mohammed Abdul, X. Jiang, K. M. Williams et al., “Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects,” British Journal of Pharmacology, vol. 154, no. 8, pp. 1691–1700, 2008. View at Publisher · View at Google Scholar · View at Scopus